Hughes et al.
JOCArticle
136.3, 136.2, 131.9, 130.3, 128.8, 124.1, 123.8, 123.1, 120.4,
120.3, 119.1, 118.9, 118.9, 118.7, 118.4, 117.8, 112.7, 110.7;
HRMS (ESI-TOF) m/z (M - H)- calcd for C22H1135Cl4N2O4
1.1 mmol) dropwise via syringe. The mixture was heated at 40 °C
overnight, allowed to cool, filtered through Celite with acetone
washings, and concentrated. The product was purified by
reversed-phase C-18 HPLC (73% CH3CN in H2O, 0.2%
TFA, tR = 23 min) to furnish 27.3 mg (100%) of 12 as a white
506.9473, found 506.9447; m/z (M þ Na)þ calcd for C22H12
-
35Cl4N2O4Na 530.9449, found 530.9439.
Marinopyrrole B (2): UV/vis (CH3CN/H2O) λmax = 274, 322,
solid: [R]D -92 (c 0.42, MeOH); IR (film) ν~ = 1647, 1597 cm-1
;
348 nm; [R]D -72 (c 0.20, MeOH); IR (film) ν~ = 1622, 1599 cm-1
;
1H NMR δ 7.40 (t, J = 7.8 Hz, 1H), 7.24-7.18 (m, 3H), 6.98-
6.93 (m, 2H), 6.75 (d, J = 8.2 Hz, 1H), 6.67 (t, J = 7.8 Hz, 1H),
6.25 (s, 1H), 4.05 (s, 3H), 3.80 (s, 3H), 3.75 (s, 3H); 13C NMR δ
184.2, 182.9, 157.3, 157.0, 131.9, 131.9, 130.7, 129.4, 129.1,
127.5, 127.4, 126.4, 125.6, 125.0, 123.6, 121.2, 119.8, 119.6,
111.7, 111.5, 110.5, 109.6, 55.6, 55.5, 34.7; HRMS (ESI-TOF)
m/z (M þ H)þ calcd for C25H1935Cl4N2O4 551.0099, found
551.0100.
1H NMR see Table 1; 13C NMR 188.5, 185.3, 162.5, 161.4, 137.3,
136.4, 134.2, 133.7, 130.0, 124.4, 121.9, 121.7, 120.0, 119.2, 118.8,
118.6, 118.5, 118.1, 117.9, 114.7, 104.7 (one quaternary carbon
signal was not detected); HRMS (ESI-TOF) m/z (M - H)- calcd
for C22H1079Br35Cl4N2O4 584.8578, found 584.8588; m/z
(M þ Na)þ calcd for C22H1179Br35Cl4N2O4Na 608.8554, found
608.8570.
Marinopyrrole C (3): UV/vis (CH3CN/H2O) λmax = 270, 324,
346 nm; [R]D -100 (c 0.040, MeOH); IR (film) ν~ = 1623, 1597
(4,40,5,50-Tetrachloro-10-methyl-10H-1,30-bipyrrole-2,20-diyl)-
bis((2-hydroxyphenyl)methanone) (13). To a solution of meta-
bolite 1 (8.7 mg, 0.017 mmol) in ether (2.0 mL) at 0 °C was added
an ethereal solution of diazomethane via pipet (torched to
remove sharp edges). After 1 min, several drops of acetic acid
were added (until gas evolution ceased), and the solution was
concentrated. The product was purified by reversed-phase
HPLC (72% CH3CN in H2O, 0.2% TFA, tR = 33 min) to
afford 7.7 mg (86%) of 13 as a pale yellow solid: [R]D -62 (c 0.35,
MeOH); IR (film) ν~ = 1624, 1596 cm-1; 1H NMR δ 11.17 (s,
1H), 10.94 (s, 1H), 7.64 (d, J = 7.8 Hz, 1H), 7.54 (d, J = 7.8 Hz,
1H), 7.49 (t, J = 7.8 Hz, 1H), 7.34 (t, J = 7.8 Hz, 1H), 7.01 (d,
J = 8.2 Hz, 1H), 6.91-6.87 (m, 2H), 6.59 (s, 1H), 6.55 (t, J = 7.8
Hz, 1H), 3.89 (s, 3H); 13C NMR δ 187.9, 186.7, 162.4, 161.9,
136.4, 136.1, 131.9, 131.6, 129.0, 125.1, 124.6, 122.6, 122.5,
120.3, 119.7, 119.1, 118.9, 118.5, 118.3, 117.6, 112.3, 108.7,
34.3; HRMS (ESI-TOF) m/z (M þ H)þ calcd for C23H1535Cl4-
N2O4 522.9786, found 522.9778.
(4,40,50-Trichloro-5-methoxy-10H-1,30-bipyrrole-2,20-diyl)bis-
((2-hydroxyphenyl)methanone) (14). To metabolite 1 (10.0 mg,
0.0196 mmol) and potassium cabonate (100 mg, 0.72 mmol) was
added MeOH (2.0 mL). The mixture was heated at 65 °C for 2 d,
allowed to cool, diluted with a saturated NH4Cl solution (4 mL),
and extracted with EtOAc (2 ꢀ 2 mL). The combined extracts
were washed with brine (1 mL), dried, filtered, and concen-
trated. The product was purified by reversed-phase HPLC (65%
CH3CN in H2O, 0.2% TFA, tR(14) = 25 min, tR(1) = 30 min) to
give 2.1 mg (21%) of 1 and 4.2 mg (42%) of 14 as a yellow
1
cm-1; H NMR see Table 1; 13C NMR (HSQC and HMBC)
186.7, 184.5, 162.4, 159.4, 136.1, 135.5, 131.1, 129.6, 128.9,
123.8, 123.8, 120.9, 118.9, 118.9, 118.3; HRMS (ESI-TOF) m/z
(M þ H)þ calcd for C22H1235Cl5N2O4 542.9240, found 542.9229.
Marinopyrrole D (4): UV/vis (CH3CN/H2O) λmax = 270, 320,
352 nm; [R]D -55 (c 0.080, MeOH); IR (film) ν~ = 1624, 1593
1
cm-1; H NMR see Table 1; 13C NMR (HSQC and HMBC)
185.3, 185.1, 161.0, 160.7, 136.3, 136.3, 130.3, 129.9, 128.4,
124.9, 123.7, 120.4, 120.1, 118.8, 118.0; HRMS (ESI-TOF) m/z
(M þ H)þ calcd for C22H1235Cl5N2O4 542.9240, found 542.9217.
Marinopyrrole E (5): UV/vis (CH3CN/H2O) λmax = 270, 320,
350 nm; [R]D -100 (c 0.005, MeOH); IR (film) ν~ = 1623, 1593
1
cm-1; H NMR: see Table 1; 13C NMR (HSQC and HMBC)
185.3, 185.1, 161.2, 161.0, 139.0, 136.0, 133.4, 129.7, 128.4,
124.9, 120.6, 120.4, 120.0, 119.1, 118.4; HRMS (ESI-TOF) m/z
(M þ H)þ calcd for C22H1279Br35Cl4N2O4 586.8735, found
586.8740.
Marinopyrrole F (6): UV/vis (CH3CN/H2O) λmax = 264, 336
nm; [R]D 0 [c 0.057, MeOH/Me2CO (2:1)]; IR (film) ν~ = 1620,
1601 cm-1 1H NMR (DMSO-d6) see Table 1; 13C NMR
;
(DMSO-d6) 183.8, 175.8, 158.2, 157.0, 145.8, 135.9, 134.0,
132.7, 130.9, 129.0, 127.7, 125.6, 123.2, 123.1, 121.6, 121.5,
120.9, 120.4, 118.8, 117.0, 105.7, 99.2; HRMS (ESI-TOF) m/z
(M þ H)þ calcd for C22H1235Cl3N2O4 472.9863, found
472.9858. (()-Marinopyrrole F (6) was prepared from marino-
pyrrole A (1): A solution of metabolite 1 (4.5 mg, 0.0088 mmol)
in DMA (1.0 mL) was heated at 145 °C for 3 d. The mixture was
allowed to cool and concentrated under full vacuum. The
product was purified by reversed-phase HPLC (65% CH3CN
in H2O, 0.2% TFA, tR = 27 min) to give 2.6 mg (62%) of (()-6
as a white solid. All analytical and spectroscopic data agreed
with the natural product.
4,40,5,50-Tetrachloro-10H-1,30-bipyrrole-2,20-diyl)bis((2-acetoxy-
phenyl)methanone) (11). To a solution of metabolite 1 (18.0 mg,
0.0353 mmol) and DMAP (1 mg) in pyridine (1.0 mL) was added
acetic anhydride (0.20 mL, 2.7 mmol) dropwise via syringe. The
mixture was stirred at room temperature for 5 h and concentrated.
The product was purified twice by reversed-phase HPLC (70%
CH3CN in H2O, 0.2% TFA, tR = 18 min; then 80% MeOH in
H2O, 0.2% TFA, tR = 25 min) to yield 12.9 mg (62%) of 11 as a
white solid: [R]D þ20 (c 0.38, MeOH); IR (film): ν~ = 1767, 1640
cm-1; 1H NMR δ 9.66 (br s, 1H), 7.58-7.51 (m, 2H), 7.38 (t, J =
7.8 Hz, 1H), 7.35-30 (m, 2H), 7.18 (d, J = 7.8 Hz, 1H), 7.12-7.08
(m, 2H), 6.52 (s, 1H), 2.20 (s, 3H), 2.19 (s, 3H); 13C NMR (125
MHz) δ 181.4, 180.2, 169.5, 169.3, 148.8, 148.4, 132.4, 132.2, 130.8,
130.1, 129.9, 129.2, 128.8, 125.4, 125.3, 125.3, 124.6, 123.8, 123.4,
123.3, 121.6, 120.4, 112.2, 111.2, 20.9, 20.7; HRMS (ESI-TOF) m/z
(M þ H)þ calcd for C26H1735Cl4N2O6 592.9841, found 592.9840.
(4,40,5,50-Tetrachloro-10-methyl-10H-1,30-bipyrrole-2,20-diyl)-
bis((2-methoxyphenyl)methanone) (12). To a solution of meta-
bolite 1 (25.2 mg, 0.0494 mmol) and potassium carbonate (200
mg) in acetone (1.0 mL) was added dimethyl sulfate (0.10 mL,
residue: [R]D þ5 (c 0.22, MeOH); IR (film) ν~ = 1619, 1592 cm-1
;
1H NMR δ 11.30 (s, 1H), 10.61 (s, 1H), 9.58 (br s, 1H), 7.72 (d,
J = 7.8 Hz, 1H), 7.59 (d, J = 7.8 Hz, 1H), 7.48 (t, J = 7.8 Hz,
1H), 7.35 (t, J = 7.8 Hz, 1H), 7.02 (d, J = 8.2 Hz, 1H),
6.95-6.89 (m, 2H), 6.66 (s, 1H), 6.53 (t, J = 7.8 Hz, 1H),
3.79 (s, 3H); 13C NMR δ 186.3, 186.1, 162.1, 161.1, 146.7,
136.0, 135.5, 131.7, 130.6, 123.3, 122.6, 122.4, 121.4, 119.9,
119.3, 118.9, 118.8, 118.8, 118.2, 117.4, 110.2, 96.5, 60.9;
HRMS (ESI-TOF) m/z (M þ H)þ calcd for C23H1635Cl3N2O5
505.0125, found 505.0118.
N-(2-(3,40,50-Trichloro-20,5-bis(2-hydroxybenzoyl)-10H-1,30-
bipyrrol-2-ylthio)ethyl)acetamide (15). To a solution of metabo-
lite 1 (7.0 mg, 0.014 mmol) and potassium carbonate (100 mg,
0.72 mmol) in DMF (1.0 mL) was added N-acetylcysteamine
(20 μL, 0.19 mmol) via syringe. The solution was heated at 80 °C
for 20 h, allowed to cool, diluted with a saturated NH4Cl
solution (4 mL), and extracted with EtOAc (2 ꢀ 2 mL). The
combined extracts were washed with brine (1 mL), dried,
filtered, and concentrated. The product was purified by
reversed-phase HPLC (50% CH3CN in H2O, 0.2% TFA, tR
=
24 min) to give 4.5 mg (55%) of 15 as a yellow residue: [R]D þ29
(c 0.27, MeOH); IR (film) ν~=1623, 1594 cm-1; 1H NMR δ 11.35
(s, 1H), 10.58 (br s, 1H), 10.19 (br s, 1H), 7.88 (d, J = 7.8 Hz,
1H), 7.57-7.53 (m, 2H), 7.30 (t, J = 7.8 Hz, 1H), 7.06 (d,
J = 8.2 Hz, 1H), 6.97 (t, J = 7.8 Hz, 1H), 6.93 (d, J = 8.2 Hz,
1H), 6.82 (s, 1H), 6.43 (t, J = 7.8 Hz, 1H), 5.70 (br s, 1H), 3.14
3248 J. Org. Chem. Vol. 75, No. 10, 2010